Founded in 1985, it is an innovative enterprise group integrating R&D, production and marketing of high-tech biopharmaceuticals and Chinese and Western patent medicines, and is involved in international trade, real estate development, business services and other fields
Shulin Gan (English; Gansulin) is a brand of Tonghua Dongbao Group Co., Ltd., which is a well-known insulin brand in the world. The marketing headquarters is located in Beijing, China, and Ganshulin's insulin preparations and raw materials have passed the export certification of 15 countries, with partners in Europe, Asia, Africa and the Americas. Presently; It has built factories in Bangladesh, Iran, Ukraine, Poland, Sweden and Malaysia. It is a Chinese company focusing on the development of insulin.
In 1995, Mr. Gan Zhongru, a doctor of biochemistry, was hired to form a scientific research team and began to independently develop genetically recombinant human insulin.
In 1998, it successfully developed the biologics drug "Ganshulin" with China's independent intellectual property rights, which filled the domestic gap and made China the third country in the world that can produce genetically recombinant human insulin and the second country that can produce insulin glargine after the United States and Denmark, and this achievement was rated as China's top ten scientific and technological progress news awards by 587 academicians of the Chinese Academy of Engineering.
It makes China the third country after the United States and Denmark to be able to produce and sell genetically recombinant human insulin, breaking the pattern of China's diabetic patients relying on imports for the use of human insulin products. It has established a good corporate image and reputation in the international community.
The products listed in China are; Gan Shulin R, Gan Shulin N, Gan Shulin 30R, Gan Shulin 50R, Gan Shulin 40R, Gan Shulin pen, Dongbao needle, etc.
In December 1992, China Tonghua Dongbao Group was established. During this period, it has successively merged several enterprises, especially in 1992, it merged Hengde Village, Ermi Town, Tonghua County, where the group is located, which was the first typical example of "enterprise and agriculture" in China, which caused strong repercussions in the country. Over the past 13 years since the establishment of the group, the scale of the enterprise has developed violently, the diversified project operation is extensive, the number of state-owned private enterprises has been merged, the production equipment and technological process have been advanced, and the research level of the scientific research team has been high, all of which can be called the miracle of the development of domestic enterprises, and has been praised as the "Dongbao model" by the industry, creating the myth of the rapid development of Chinese enterprises.
Toho's pharmaceutical industry is renowned for its world-class biopharmaceutical cutting-edge technology. It has successively developed and launched a large number of national new drugs and fist products such as "Zhennaoning", Dongbao Gantai Tablets, and Brain Xuekang Tablets. In the field of biopharmaceuticals, the group has invested hundreds of millions of yuan in scientific research funds, and in 1998, it successfully developed a high-tech preparation drug "Ganshulin" with China's independent intellectual property rights, which filled the domestic gap and made China the third country in the world that can produce genetically recombinant human insulin and the second country that can produce insulin glargine after the United States and Denmark, and the achievement was rated as one of China's top ten scientific and technological progress news awards by 587 academicians of the Chinese Academy of Engineering. At present, with a total investment of 350 million yuan, the second phase expansion project of Dongbao Gene Recombinant Human Insulin, a key support project for the revitalization of the old industrial base in Northeast China, is intensively introducing and installing foreign advanced equipment, and will produce 3,000 kg in the past two years to meet the growing domestic and international market demand. Dongbao Group has become one of the world's largest human insulin production bases with today's advanced technology.
